title: Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
abstract: Infants born to human immunodeficiency virus type 1 (HIV-1)-infected mothers were immunized at birth and at ages 4, 12, and 20 weeks with low-, medium-, or high-dose recombinant gp120 vaccine with MF59 adjuvant (HIV-1(SF-2); n=52) or with MF59 alone as a placebo (n=9). An accelerated schedule (birth and ages 2, 8, and 20 weeks) was used for an additional 10 infants receiving the defined optimal dose and for 3 infants receiving placebo. At 24 weeks, anti-gp120 ELISA titers were greater for vaccine-immunized than for placebo-immunized infants on both schedules, and 87% of vaccinees had a vaccine-induced antibody response. At 12 weeks, antibody titers of infants on the accelerated vaccine schedule exceeded those of infants receiving placebo (4949 vs. 551; P=.01), and 63% of the vaccinees met the response criteria. Thus, an accelerated schedule of gp120 vaccinations generated an antibody response to HIV-1 envelope distinct from transplacental maternal antibody by age 12 weeks. These results provide support for further studies of vaccine strategies to prevent mother-to-infant HIV-1 transmission.
authors.affiliation: Department of Pediatrics, University of Colorado Health Science Center, Denver, CO 80262, USA. Betsy.mcfarland@uchsc.edu
authors.forename: E J
authors.initials: EJ
authors.lastname: McFarland
authors.forename: W
authors.initials: W
authors.lastname: Borkowsky
authors.forename: T
authors.initials: T
authors.lastname: Fenton
authors.forename: D
authors.initials: D
authors.lastname: Wara
authors.forename: J
authors.initials: J
authors.lastname: McNamara
authors.forename: P
authors.initials: P
authors.lastname: Samson
authors.forename: M
authors.initials: M
authors.lastname: Kang
authors.forename: L
authors.initials: L
authors.lastname: Mofenson
authors.forename: C
authors.initials: C
authors.lastname: Cunningham
authors.forename: A M
authors.initials: AM
authors.lastname: Duliege
authors.forename: F
authors.initials: F
authors.lastname: Sinangil
authors.forename: S A
authors.initials: SA
authors.lastname: Spector
authors.forename: E
authors.initials: E
authors.lastname: Jimenez
authors.forename: Y
authors.initials: Y
authors.lastname: Bryson
authors.forename: S
authors.initials: S
authors.lastname: Burchett
authors.forename: L M
authors.initials: LM
authors.lastname: Frenkel
authors.forename: R
authors.initials: R
authors.lastname: Yogev
authors.forename: F
authors.initials: F
authors.lastname: Gigliotti
authors.forename: K
authors.initials: K
authors.lastname: Luzuriaga
authors.forename: R A
authors.initials: RA
authors.lastname: Livingston
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage* / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011136:Polysorbates; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology; D013185:Squalene / Q000276:immunology; D014611:Vaccination; D022223:Vaccines, Subunit / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015699:HIV Envelope Protein gp120; C089950:MF59 oil emulsion; D011136:Polysorbates; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D013185:Squalene